Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

January 31, 2024

https://www.globenewswire.com/news-release/2024/01/31/2821541/0/en/Ascendis-Pharma-Launches-2nd-TransCon-Product-YORVIPATH-Now-Available-in-Germany-and-Austria-for-Adults-with-Chronic-Hypoparathyroidism.html

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in Germany and Austria. YORVIPATH is the second product developed with Ascendis Pharma’s TransCon technology platform to be launched commercially.

Read more at globenewswire.com

Related news for (ASND)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.